The association of MAPT rs1467967 polymorphism with AD pathology measured by levels of CSF biomarkers was demonstrated, with CSF t‐tau and p‐tau181 levels being significantly higher in patients with AG compared to GG MAPT rs1467967 genotype and t‐tau levels being significantly higher in patients with AA compared to GG MAPT rs1467967 genotype. This evidence concerns the gene MAPT and Alzheimer disease.